Dashboard
Manage Tickers

BGNE


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

innovent-bio-hopes-for-plus-sized-profits-from-obesity-drug
Innovent Bio hopes for plus-sized profits ...
09/06/2024 19:16:41

Key Takeaways: Sales approval for the company’s anti-obesity drug mazdutide may drag out beyond this year, potentially allow...

top-2-health-care-stocks-that-may-plunge-in-august
Top 2 Health Care Stocks That May Plunge I...
08/26/2024 11:53:01

beigene-says-fda-granted-fast-track-designation-to-bgb-16673-for-adult-patients-with-relapsed-or-refractory-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma
BeiGene Says FDA Granted Fast Track Design...
08/26/2024 10:02:32

The FDA's Fast track designation is aimed to facilitate the development and expedite the review of drugs to treat serious c...

cancer-medicines-from-merck-bristol-myers-and-beigene-in-question-as-fda-committee-to-discuss-limiting-pd-1-drugs-for-stomach-cancer
Cancer Medicines From Merck, Bristol Myers...
08/23/2024 18:10:48

The FDA's Oncologic Drugs Advisory Committee will meet on September 26 to reevaluate the approvals of checkpoint inhibitors...

jp-morgan-maintains-overweight-on-beigene-raises-price-target-to-200
JP Morgan Maintains Overweight on BeiGene,...
08/20/2024 14:13:53

JP Morgan analyst Jessica Fye maintains BeiGene (NASDAQ:BGNE) with a Overweight and raises the price target from $194 to $200.

citigroup-maintains-buy-on-beigene-raises-price-target-to-288
Citigroup Maintains Buy on BeiGene, Raises...
08/08/2024 19:12:33

Citigroup analyst Yigal Nochomovitz maintains BeiGene (NASDAQ:BGNE) with a Buy and raises the price target from $269 to $288.

beigene-q2-2024-gaap-epads-115-beats-221-estimate-sales-929166m-beat-790171m-estimate
BeiGene Q2 2024 GAAP EPADS $(1.15) Beats $...
08/07/2024 10:13:20

beigene-opens-us-biologics-manufacturing-and-clinical-rd-facility-in-new-jersey-with-800m-investment
BeiGene Opens U.S. Biologics Manufacturing...
07/23/2024 11:09:09

beigene-has-appointed-aaron-rosenberg-as-chief-financial-officer-effective-july-22-succeeding-julia-wang-who-is-departing-to-pursue-external-opportunities-and-will-stay-with-the-company-through-august-to-support-the-transition
Beigene Has Appointed Aaron Rosenberg As C...
07/18/2024 10:40:19

b-of-a-securities-maintains-neutral-on-beigene-lowers-price-target-to-1525
B of A Securities Maintains Neutral on Bei...
07/09/2024 17:20:52

B of A Securities analyst David Li maintains BeiGene (NASDAQ:BGNE) with a Neutral and lowers the price target from $180 to $...

moderna-and-walgreens-boots-alliance-were-among-the-10-biggest-large-cap-losers-last-week-june-23---june-29-are-these-in-your-portfolio
Moderna And Walgreens Boots Alliance Were ...
06/30/2024 18:21:19

10 worst performing large-cap stocks last week: Walgreens, Floor & Decor, Moderna, Birkenstock, BeiGene, Pool Corp, JD.com,...

whats-going-on-with-small-cap-cancer-focused-nurix-therapeutics-on-monday
What's Going On With Small-Cap Cancer Focu...
06/17/2024 15:47:08

Nurix Therapeutics presented updated clinical data for NX-5948, an orally bioavailable BTK degrader, at the EHA Congress. NX-59...

beigene-says-it-will-present-new-data-from-sequoia-study-evaluating-brukinsa-plus-venetoclax-in-high-risk-first-line-cllsll-at-eha2024-preliminary-data-suggests-efficacy-and-tolerability
BeiGene Says It Will Present New Data From...
06/14/2024 10:04:40

BeiGene, Ltd. a global oncology company, announced the presentation of new data from the SEQUOIA study of BRUKINSA® (zanubrutin...

Core News & Articles
BriaCell Therapeutics Announces Clinical S...
05/28/2024 12:28:39

lululemon-athletica-was-among-the-worst-performing-stocks-last-week-may-19-may-26-2024-are-these-10-large-cap-stock-losers-in-your-portfolio
Lululemon Athletica Was Among The Worst-Pe...
05/26/2024 15:16:23

10 worst-performing large-cap stocks last week. National Grid, James Hardie, KE Holdings, JD.Com, XP, Nordson, BeiGene, Lululem...

beigene-says-brukinsa-data-at-american-society-of-clinical-oncology-asco-annual-meeting-in-chicago-underscore-differentiated-clinical-profile-for-treatment-of-cll-and-sll
BeiGene Says BRUKINSA Data At American Soc...
05/24/2024 10:05:14

 The presentations highlight analyses of the efficacy and safety of BRUKINSA compared to other Bruton's tyrosine kinase inh...

beigene-to-highlight-new-hematology-portfolio-and-pipeline-data-at-eha2024-june-13-16-2024
BeiGene To Highlight New Hematology Portfo...
05/14/2024 20:16:58

Study evaluating BRUKINSA® in combination with venetoclax in high-risk, treatment-naïve CLL/SLL patients to be shared as oral p...

td-cowen-maintains-buy-on-beigene-raises-price-target-to-254
TD Cowen Maintains Buy on BeiGene, Raises ...
05/09/2024 16:16:07

TD Cowen analyst Yaron Werber maintains BeiGene (NASDAQ:BGNE) with a Buy and raises the price target from $236 to $254.

beigene-q1-2024-gaap-epads-241-beats-289-estimate-sales-751652m-beat-676451m-estimate
BeiGene Q1 2024 GAAP EPADS $(2.41) Beats $...
05/08/2024 10:10:27

BeiGene (NASDAQ:BGNE) reported quarterly losses of $(2.41) per share which beat the analyst consensus estimate of $(2.89) by 16...

tracking-last-weeks-top-performers-are-these-15-large-cap-stocks-in-your-portfolio-april-21-27-2024
Tracking Last Week's Top Performers: Are T...
04/28/2024 22:18:08

Last week's top performers included Vertiv Holdings, Tesla, Tyler Technologies, and Newmont Corporation.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION